Navigation Links
HF patients treated by a cardiologist, rather than hospitalist, have fewer readmissions
Date:11/6/2012

MINNEAPOLIS, MN November 6, 2012 When a cardiologist attends to heart failure patients, even when the severity of illness is higher, patients have reduced rates of hospital readmissions, compared with those patients who are treated by a hospitalist, according to a trial being presented today at the American Heart Association's scientific sessions in Los Angeles.

Congestive heart failure (CHF) is the most common cause for hospital readmission in patients over the age of 65 years. Whereas efforts to reduce readmission rates have focused on transitions of care and short-term outpatient follow-up, limited data exist on the impact on what type of specialist is attending to the patient during the admission to reduce these rates.

"Since October 1, 2012, there has been a tremendous national focus on readmission rates, because the Centers for Medicare & Medicaid Services began penalizing hospitals for readmissions," explained Casey M. Lawler, MD, a cardiologist at the Minneapolis Heart Institute (MHI) at Abbott Northwestern Hospital. "However, we at the Minneapolis Heart Institute began to establish protocols to improve our heart failure readmission rates five years ago because we were concerned about providing better patient care; which would then by design have an impact on decreasing preventable readmissions."

In their initial assessments, MHI healthcare professionals learned that one in five patients did not understand their HF diagnosis, and less than that understood their medication regimen. "Thus, we became much more involved in post-discharge care by phone call within 24 hours of discharge, establishing provider follow-up within three to five days post discharge and having a nurse practitioner follow-up with patients identified as high risk; however, we also wanted to examine whether treatment within the walls of our facility impacted patient care and readmission rates," Lawler said.

In this study, the researchers retrospectively identified all CHF admissions between Jan. 1, 2009, and Dec. 31, 2011. They analyzed patient demographics, length of stay, time to readmission, all patient refined diagnosis related groups, hospital attending at time of discharge and total hospital costs based on the attending medical professional at the time of patient discharge.

Among 2,311 patients, 65 percent of patients were treated by a hospitalist, whereas the remaining 35 percent patients were treated by a cardiologist.

In the analysis, the researchers found that 23.2 percent of patients were readmitted within 30 days of discharge. Readmission rates were significantly lower when the attending physician was a cardiologist as compared to a hospitalist (16 vs. 27.1 percent). They also found that cardiologists were seeing more severe cases.

Median length-of-stay in the hospital was similar between attending cardiologists and hospitalists (4.8 days vs. 4.2 days). After some adjustments, Lawler and his colleagues found that the mean total costs for patients treated by a cardiologist were higher than those treated by a hospitalist ($9,850 vs. $7,741).

"Although these results reveal that specialists have a positive impact on readmission rates, an overhaul to an entire healthcare system's treatment of HF patientsfrom admission to post-discharge follow-upis required to truly impact preventable readmissions," Lawler said.


'/>"/>
Contact: Steve Goodyear
sgoodyear@mhif.org
952-807-8365
Minneapolis Heart Institute Foundation
Source:Eurekalert

Related medicine news :

1. Higher-spending hospitals have fewer deaths for emergency patients
2. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
3. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
4. Study finds doctors have exaggerated fears when starting patients on insulin
5. Diagnostic Scans Tied to Radiation Risk for Gastro Patients
6. Predictors identified for rehospitalization among post-acute stroke patients
7. Pulse pressure elevation could presage cerebrovascular disease in Alzheimers patients
8. Breast cancer patients suffer treatment-related side effects long after completing care
9. Heart failure patients with diabetes may benefit from higher glucose levels
10. Gastro Woes Often Strike Rheumatoid Arthritis Patients
11. Short Walks May Ease Fatigue in Pancreatic Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Valley, CA (PRWEB) , ... December 07, 2016 , ... ... be used in several ways to restore a more youthful appearance to the face. ... now offer Sculptra, along with a variety of other treatments, to rejuvenate and renew ...
(Date:12/7/2016)... ... ... time to blow out his candles on his 14th birthday, Estefano Reano had only one ... at Joe DiMaggio Children’s Hospital surprised his family with a phone call that made his ... “He was playing at home, when we got the phone call telling us there was ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... planning services to families and business owners in the greater Dallas metropolitan area, ... the Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals ...
(Date:12/7/2016)... ... XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... Man’s ... Filamentous Dermatitis Associated with Borrelia Infection” reveals that a condition similar ... the prestigious Journal of Veterinary Science & Medical Diagnosis. , Morgellons disease is ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... LONDON , Dec. 7, 2016 ... Global Market Intelligence (2011-2020)" provides market intelligence on ... and forecast (2011-2020) has been provided in the ... to provide 1) comprehensive global market intelligence through ... rates, market dynamics, industry structure and developments, market ...
(Date:12/7/2016)... Dec. 7, 2016  Northwest Biotherapeutics (Nasdaq: ... a biotechnology company developing DCVax® personalized immune therapies ... Nasdaq Staff has not accepted the Company,s plan ... previously reported, and the Company has notified Nasdaq ... common stock from listing on Nasdaq.  Upon withdrawal ...
(Date:12/7/2016)... Hoovers Research analysis is one ... combinational analytical tools. The report contains up to ... to present unique and reliable analysis. Assessment of ... during the next five years, including a deep ... sub markets, regional and country level analysis. The ...
Breaking Medicine Technology: